Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes

Advanced Drug Delivery Reviews

Volumn 48, Issue 1, 2001, Pages 91-114

  Morris, Kenneth R ^a   Griesser, Ulrich J ^b   Eckhardt, Craig J ^c   Stowell, Joseph G ^a  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Active Pharmaceutical Ingredient; Amorphous; Crystallization; Drying; Hydrate; Lyophilization; Phonon; Polymorph; Process induced transformation; Solvate; Tabletting; Wet Granulation

Indexed keywords

MANUFACTURE;

PROCESSING-INDUCED TRANSFORMATIONS (PIT);

DRUG PRODUCTS;

FOSINOPRIL; PENTAMIDINE ISETHIONATE; THEOPHYLLINE;

ARTICLE; CRYSTAL; DEHYDRATION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG GRANULATION; DRUG MANUFACTURE; DRUG STABILITY; FREEZE DRYING; MODEL; PHASE TRANSITION; PRIORITY JOURNAL; SOLID STATE; STRESS; STRUCTURE ANALYSIS; TABLET FORMULATION; THERMODYNAMICS; TIME;

DRUG INDUSTRY; FREEZE DRYING; MODELS, CHEMICAL; TABLETS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0035897679     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(01)00100-4     Document Type: Article

References (48)

1. Byrn S.R., Pfeiffer R.R., Stowell J.G. Solid-State Chemistry of Drugs. 1999;SSCI, Inc, West Lafayette.
2. Byrn S., Pfeiffer R., Ganey M., Hoiberg C., Poochikian G. Pharmaceutical solids: a strategic approach to regulatory considerations. Pharm. Res. 12:1995;945-954.
3. Test procedures and acceptance criteria for new drub substances and new drug products: chemical substances. Fed. Reg. 62:1997;62889-62910.
4. Otsuka M., Kaneniwa N. Effect of grinding on the degree of crystallinity of cephalexin powder. Chem. Pharm. Bull. 31:1983;4489-4495.
5. Otsuka M., Kaneniwa N. Effects of grinding on the physicochemical properties of cephalexin powder. Chem. Pharm. Bull. 32:1984;1071-1079.
6. Otsuka M., Kaneniwa N. Effect of seed crystals on solid-state transformation of polymorphs of chloramphenicol palmitate during grinding. J. Pharm. Sci. 75:1986;506-511.
7. Otsuka M., Kaneniwa N. Effect of grinding on the crystallinity and chemical stability in the solid state of cephalothin sodium. Int. J. Pharm. 62:1990;65-73.
8. Otsuka M., Matsuda Y. Effects of environmental temperature and compression energy on polymorphic transformation during tabletting. Drug Dev. Ind. Pharm. 19:1993;2241-2269.
9. Otsuka M., Hasegawa H., Matsuda Y. Effect of polymorphic transformation during the extrusion-granulation process on the pharmaceutical properties of carbamazepine granules. Chem. Pharm. Bull. 45:1997;894-898.
10. Otsuka M., Matsumoto T., Kaneniwa N. Effect of environmental temperature on polymorphic solid-state transformation of indomethacin during grinding. Chem. Pharm. Bull. 34:1986;1784-1793.
11. Otsuka M., Matsumoto T., Kaneniwa N. Effects of the mechanical energy of multi-tableting compression on the polymorphic transformations of chlorpropamide. J. Pharm. Pharmacol. 41:1989;665-669.
12. Otsuka M., Nakanishi M., Matsuda Y. Effects of crystalline form on the tableting compression mechanism of phenobarbital polymorphs. Drug Dev. Ind. Pharm. 25:1999;205-215.
13. Otsuka M., Ohtani H., Kaneniwa N. Effect of humidity on solid-state isomerization of various kinds of lactose during grinding. J. Pharm. Pharmacol. 45:1992;2-5.
14. Otsuka M., Onoe M., Matsuda Y. Physicochemical stability of phenobarbital polymorphs at various levels of humidity and temperature. Pharm. Res. 10:1993;577-582.
15. Otsuka M., Otsuka K., Kaneniwa N. Relation between polymorphic transformation pathway during grinding and the physicochemical properties of bulk powders for pharmaceutical preparations. Drug Dev. Ind. Pharm. 20:1994;1649-1660.
16. Cardew P.T., Davey R.J. The kinetics of solvent-mediated phase transformations. Proc. R. Soc. Lond. 398:1985;415-428.
17. Ehrenfest P. Phase changes classified according to the singularities of the thermodynamic potential. Proc. Acad. Sci. Amsterdam. 36:1933;153-157. Chap. 2.
18. Eckhardt C.J., Luty T., Peachey N.M. Collective interactions and solid state reactivity. Mol. Cryst. Liq. Cryst. 313:1998;25-38.
19. Luty T., Eckhardt C.J. General theoretical concepts for solid-state reactions: quantitative formulation of the reaction cavity, steric compression, and reaction-induced stress using an elastic multipole representation of chemical pressure. J. Am. Chem. Soc. 117:1995;2441-2452.
20. Sharma S.M., Vijayakumar V., Sikka S.K., Chidambaram R. High-pressure phase-transitions in organic-solids alpha-beta transition in resorcinol. Pramana. 25:1985;75-79.
21. Griesser U.J., Burger A., Mereiter K. The polymorphic drug substances of the European pharmacopoeia. IX Physicochemical properties and crystal structure of acetazolamide crystal forms. J. Pharm. Sci. 86:1997;352-358.
22. Hancock B.C., Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86:1997;1-12.
23. Callen H.B. Thermodynamics and an Introduction to Thermostatistics. 2nd Edition :1985;John Wiley and Sons, New York.
24. Turnbull D. Phase changes. Seitz F., Turnbull D. Solid-State Physics: Advances in Research and Applications. Vol. 3:1956;225-306 Academic Press, New York.
25. Petit S., Coquerel G. Mechanism of several solid-solid transformations between dihydrated and anhydrous copper(II) 8-hydroxyquinolinates. Proposition for a unified model for the dehydration of molecular crystals. Chem. Mater. 8:1996;2247-2258.
26. J.Z. Gougoutas, Senior Research Fellow, Bristol-Myers Squibb Research Institute, Princeton, NJ, (personal communication).
27. Kunii D., Levenspiel O. Fluidization Engineering. 2nd Edition :1991;Butterworth-Heinemann, Oxford. Chap. 13.
28. Mullin J.W. Crystallization. 3rd Edition :1997;227-228 Butterworth-Heinemann, Oxford.
29. Brittain H.G., Morris K.R., Bugay D.E., Thakur A.B., Serajuddin A.T.M. Solid-state NMR and IR for the analysis of pharmaceutical solids: polymorphs of fosinopril sodium. J. Pharm. Biomed. Anal. 11:1993;1063-1069.
30. Stephenson G.A., Stowell J.G., Toma P.H., Dorman D.E., Greene J.R., Byrn S.R. Solid-state analysis of polymorphic, isomorphic, and solvated forms of dirithromycin. J. Am. Chem. Soc. 116:1994;5766-5773.
31. Otsuka M., Onoe M., Matsuda Y. Physicochemical stability of phenobarbital polymorphs at various levels of humidity end temperature. Pharm. Res. 10:1993;577-582.
32. Wong M.W.Y., Mitchell A.G. Physicochemical characterization of a phase-change produced during the wet granulation of chlorpromazine hydrochloride and its effects on tabletting. Int. J. Pharm. 88:1992;261-273.
33. Parker M.D., York P., Rowe R.C. Binder-substrate interactions in wet granulation. III. The effect of excipient source variation. Int. J. Pharm. 80:1992;179-190.
34. Phadnis N.V., Suryanarayanan R. Polymorphism in anhydrous theophylline: implications on the dissolution rate of theophylline tablets. J. Pharm. Sci. 86:1997;1256-1263.
35. Doser H. The melting points of pantocaines, bromurals, and theophyllines. Arch. Pharm. 53:1943;251-256.
36. Burger A., Ramberger R. On the polymorphism of pharmaceuticals and other molecular crystals. II. Applicability of thermodynamic rules. Mikrochim. Acta. 2:1979;273-316.
37. Suzuki E., Shimomura K., Sekiguchi K. Thermochemical study of theophylline and its hydrate. Chem. Pharm. Bull. 37:1989;493-497.
38. Griesser U.J., Burger A. Effect of different moisture conditions on phase changes of theophylline crystal forms. 41st Annual Congress of the Study Group for Pharmaceutical Technical Procedures e. v. (A.P.V.) Budapest, May 8-11 :1995.
39. Herman J., Remon J.P., Visavarungroj N., Schwartz J.B., Klinger G. Formation of theophylline monohydrate during the pelletisation of microcrystalline cellulose-anhydrous theophylline blends. Int. J. Pharm. 42:1988;15-18.
40. Niskanen M. Explaining the dissolution properties of theophylline pellets by their microstructure. Pharm. Technol. Int. Ed. 4:1992;20-28.
41. Adeyeye C.M., Rowley J., Madu D., Javadi M., Sabnis S.S. Evaluation of crystallinity and drug release stability of directly compressed theophylline hydrophilic matrix tablets stored under varied moisture conditions. Int. J. Pharm. 116:1995;65-75.
42. Miyamae A., Kema H., Kawabata T., Yasuda T., Otsuka M., Matsuda Y. X-ray-powder diffraction study on the grinding effect of the polymorphs of a novel and orally effective uricosuric agent FR76505. Drug Dev. Ind. Pharm. 20:1994;2881-2897.
43. Otsuka M., Matsumoto T., Higuchi S., Otsuka K., Kaneniwa N. Effect of compression temperature on the consolidation mechanism of chlorpropamide polymorphs. J. Pharm. Sci. 84:1995;614-618.
44. Takahashi Y., Nakashima K., Ishihara T., Nakagawa H., Sugimoto I. Polymorphism of fostedil: characterization and polymorphic change by mechanical treatments. Drug Dev. Ind. Pharm. 11:1985;1543-1563.
45. Clas S.D., Faizer R., O'Connor R.E., Vadas E.B. Quantification of crystallinity in blends of lyophilized and crystalline MK-0591 using X-ray-powder diffraction. Int. J. Pharm. 121:1995;73-79.
46. Clas S.D., Cotton M., Moran E., Spagnoli S., Zografi G., Vadas E.B. Assessment of the physical stability of lyophilized MK-0591 by differential scanning calorimetry. Thermochim. Acta. 288:1996;83-96.
47. Pikal M.J. Impact of polymorphism on the quality of lyophilized products. Brittain H.G. Polymorphism in Pharmaceutical Solids. 1999;395-419 Marcel Dekker, New York.
48. Chongprasert S., Griesser U.J., Bottorff A.T., Williams N.A., Byrn S.R., Nail S.L. Effects of freeze dry processing conditions on the crystallization of pentamidine isethionate. J. Pharm. Sci. 87:1998;1155-1160.